Enhanced neutralization of SARS-CoV-2 XBB sub-lineages and BA.2.86 by a tetravalent COVID-19 vaccine booster

Xun Wang, Shujun Jiang, Wentai Ma, Xiangnan Li, Kaifeng Wei, Faren Xie, Chaoyue Zhao, Xiaoyu Zhao, Chen Li, Rui Qiao, Yuchen Cui, Yanjia Chen, Jiayan Li, Guonan Cai, Changyi Liu, Zixin Hu, Wenhong Zhang, Mingkun Li, Yanliang Zhang, Pengfei WangbioRxiv 2023 · DOI

TL;DR

A new tetravalent COVID-19 vaccine booster (SCTV01E) shows robust neutralization against emerging SARS-CoV-2 variants like XBB sub-lineages and BA.2.86, outperforming natural infection and older vaccines. This highlights the potential of multivalent vaccines to keep pace with viral evolution and combat future variants.

What Problem Does This Paper Address?

The SARS-CoV-2 virus is constantly evolving, leading to the emergence of new variants like the XBB sub-lineages and BA.2.86. These variants possess numerous mutations, particularly in the spike protein, which can potentially allow them to evade existing immunity from prior infections or vaccinations. Understanding how well current vaccines and natural immunity protect against these new threats is crucial for public health strategies. Specifically, this paper investigates whether a recently approved tetravalent protein-based vaccine booster, SCTV01E, can provide enhanced protection against these rapidly evolving variants compared to previous vaccination strategies or natural infection.

Methods

The researchers employed a multi-pronged approach to assess immune responses:

  • Serum Neutralization Assays: They used a panel of pseudoviruses (PsVs) representing a wide array of SARS-CoV-2 variants, including the wild-type, early variants, Omicron sub-lineages, and the latest XBB variants and BA.2.86. Sera from different participant groups (vaccinated with inactivated vaccine, boosted with SCTV01E, or with breakthrough infections) were tested for their ability to neutralize these PsVs. The key metric here is the ID50 titer, which indicates the serum dilution required to neutralize 50% of the virus.
  • Antigenic Cartography: To visualize the antigenic relationships between different viral variants and the breadth of immune responses, they constructed an antigenic map using the neutralization data. This method helps to understand how antigenically distant variants are from each other and how well antibodies generated against one variant can neutralize others.
  • Cellular Immunity Assays (Flow Cytometry): They analyzed peripheral blood samples to quantify virus-specific B cells (memory B cells expressing the receptor-binding domain of the spike protein) and T cells (IFN-γ producing CD4+ and CD8+ T cells). This provided insights into the cellular immune memory generated by different vaccination and infection histories.
  • ELISA: This technique was used to measure binding antibody titers against the spike protein and its receptor-binding domain (RBD) of different SARS-CoV-2 variants.

Datasets

The study utilized serum samples from four groups of participants:

  1. Individuals who received three doses of an inactivated vaccine (CoronaVac).
  2. Individuals who received the tetravalent protein-based vaccine SCTV01E as a booster after three doses of inactivated vaccine.
  3. Individuals who experienced breakthrough infections with BA.5 or BF.7 variants after three doses of inactivated vaccine.
  4. Individuals who experienced breakthrough infections with XBB variants after three doses of inactivated vaccine.

The viral variants used in the study were derived from publicly available genomic data and constructed as pseudoviruses.

Key Insights and Ideas

  • SCTV01E Booster's Broad Neutralization: The tetravalent SCTV01E booster vaccine demonstrated a remarkable ability to neutralize a wide range of SARS-CoV-2 variants, including the highly mutated XBB sub-lineages and BA.2.86.
  • Emerging Variants Not Dramatically More Resistant: Despite the significant number of mutations in XBB sub-lineages and BA.2.86, they did not show a substantially increased resistance to neutralization compared to earlier variants like XBB.1.5. This suggests that while the virus is evolving, the current vaccine strategies might still offer a degree of protection.
  • Booster Outperforms Natural Infection: Encouragingly, the SCTV01E booster vaccination consistently induced higher neutralizing antibody titers against all tested variants compared to natural breakthrough infections. This points to the potential of well-designed boosters to elicit a more robust and broader immune response.
  • B Cell Enhancement: The SCTV01E booster significantly enhanced the frequency of virus-specific memory B cells, which are crucial for long-term immunity and rapid response to future infections.
  • T Cell Response Less Distinct: While antibody and B cell responses were significantly boosted by SCTV01E, the impact on T cell responses (IFN-γ producing CD4+ and CD8+ T cells) was less pronounced and did not show significant differences across the groups. This suggests that the vaccine's primary strength lies in antibody-mediated immunity.
  • Antigenic Drift: The antigenic map revealed that newer variants like BQ.1.1, CH.1.1, and XBB sub-lineages have undergone considerable antigenic drift, distancing themselves from earlier Omicron clusters, but BA.2.86 clustered closely with the XBB sub-lineages.

Key Results

  • The SCTV01E booster group showed significantly higher neutralization titers against all tested SARS-CoV-2 variants compared to both the three-dose inactivated vaccine group and the breakthrough infection groups (p-values < 0.0001).
  • For the SCTV01E booster group, neutralization titers against WT virus were high (GMT 6674), with only a modest 1.1- to 2.3-fold reduction against early Omicron variants. Even against the more resistant BQ.1.1, CH.1.1, and XBB.1.5, titers remained above 1000.
  • The SCTV01E booster vaccination elicited a significantly higher frequency of RBD-specific memory B cells compared to the CoronaVac vaccine group and even the BA.5 breakthrough infection group.
  • No significant differences were observed in the proportions of IFN-γ-producing CD4+ or CD8+ T cells across the groups.

Limitations and Future Work

  • Preliminary Cellular Immunity Data: The authors acknowledge that their analysis of B and T cell responses is preliminary. Future studies should delve deeper into the dynamic profiles of plasma cells, different subtypes of memory B cells, follicular helper T cells, and regulatory T cells for a more comprehensive understanding of cellular immunity.
  • Duration of Efficacy: While the study demonstrates enhanced protection, further research is needed to determine the duration of this protective efficacy conferred by the SCTV01E booster.
  • T Cell Response: The less distinct advantage in eliciting stronger T-cell responses compared to other groups warrants further investigation.

The study strongly advocates for the development of novel multivalent vaccines to effectively combat future viral variants, given their ability to broaden antibody responses and improve cross-strain protection.

Summary updated

Abstract

Abstract As the SARS-CoV-2 virus continues to evolve, novel XBB sub-lineages such as XBB.1.5, XBB.1.16, EG.5, HK.3 (FLip), and XBB.2.3, as well as the most recent BA.2.86, have been identified and aroused global concern. Understanding the efficacy of current vaccines and the immune system’s response to these emerging variants is critical for global public health. In this study, we evaluated the neutralization activities of sera from participants who received COVID-19 inactivated vaccines, or a booster vaccination of the recently approved tetravalent protein vaccine in China (SCTV01E), or had contracted a breakthrough infection with BA.5/BF.7/XBB virus. Comparative analysis of their neutralization profiles against a broad panel of 30 SARS-CoV-2 sub-lineage viruses revealed that strains such as BQ.1.1, CH.1.1, and all the XBB sub-lineages exhibited heightened resistance to neutralization than previous variants, however, despite the extra mutations carried by emerging XBB sub-lineages and BA.2.86, they did not demonstrate significantly increased resistance to neutralization compared to XBB.1.5. Encouragingly, the SCTV01E booster vaccination consistently induced robust and considerably higher neutralizing titers against all these variants than breakthrough infection did. Cellular immunity assays also showed that the SCTV01E booster vaccination elicited a higher frequency of virus-specific memory B cells but not IFN-γ secreting T cells. Our findings underline the importance of developing novel multivalent vaccines to more effectively combat future viral variants.
BibTeX
@misc{wang2023enhanced,
  author = {Xun Wang and Shujun Jiang and Wentai Ma and Xiangnan Li and Kaifeng Wei and Faren Xie and Chaoyue Zhao and Xiaoyu Zhao and Chen Li and Rui Qiao and Yuchen Cui and Yanjia Chen and Jiayan Li and Guonan Cai and Changyi Liu and Zixin Hu and Wenhong Zhang and Mingkun Li and Yanliang Zhang and Pengfei Wang},
  title = {{Enhanced neutralization of SARS-CoV-2 XBB sub-lineages and BA.2.86 by a tetravalent COVID-19 vaccine booster}},
  year = {2023},
  doi = {10.1101/2023.09.14.557682},
  howpublished = {bioRxiv},
}
Figure